Open AccessA Case of Meningococcal and HSV-2 Meningitis in a Patient Being Treated with Ustekinumab for Pityriasis Rubra Pilaris
Author(s) -
Charalampos I Kalogeropoulos,
K. Papathanasiou,
Ismini Tsagkaraki,
Γεώργιος Γιαννόπουλος,
Aristotelis Bamias,
Eleni Boutati
Publication year - 2020
Publication title -
european journal of case reports in internal medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.125
H-Index - 1
ISSN - 2284-2594
DOI - 10.12890/2020_001615
Subject(s) - ustekinumab , medicine , dermatology , psoriasis , psoriatic arthritis , pityriasis rubra pilaris , ulcerative colitis , immunology , pityriasis rosea , disease , adalimumab , rheumatoid arthritis
Pityriasis rubra pilaris (PRP) is a rare chronic inflammatory papulosquamous dermatosis affecting both adults and children. Six subtypes of PRP have been described. Recently, the management of PRP with biologic immunosuppressive agents regularly used in psoriasis has been supported by several case reports and series. Ustekinumab is an anti-IL12/23 IgG1 kappa human monoclonal antibody. It has been approved for the treatment of Crohn’s disease, plaque psoriasis, psoriatic arthritis and ulcerative colitis. It has also been reported to be effective as an off-label treatment for PRP. Current data are equivocal regarding infectious disease risk with ustekinumab administration. We describe a case of meningococcal and HSV-2 infection of the central nervous system in a patient being treated with ustekinumab for PRP.